NeOnc Technologies Draws Institutional Backing and $1M Insider Purchases
Maxim Group and Alliance Global Partners launched coverage on NeOnc Technologies with favorable ratings and targets alongside BTIG Research. CEO Amir Heshmatpour acquired over $500,000 in shares this year (insiders total nearly $1 million) while Bank of America and State Street lifted positions ahead of Phase 2a glioblastoma interim data.
1. New Analyst Coverage
Maxim Group and Alliance Global Partners recently initiated coverage on NeOnc Technologies with favorable ratings and price targets, joined by BTIG Research. The reports highlight the differentiated intranasal CNS-focused platform and potential upside as the company advances its lead assets.
2. Insider and Institutional Accumulation
CEO Amir Heshmatpour has purchased over $500,000 of shares this year, bringing total insider acquisitions close to $1 million. Institutional investors including Bank of America, State Street Corp, Barclays PLC, Westmount Partners and Foundations Investment Advisors have concurrently increased their stakes.
3. Pipeline Progress and Upcoming Catalysts
NeOnc’s lead candidate NEO100 is in a fully enrolled Phase 2a trial targeting glioblastoma, with interim data expected soon. The company is also advancing NEO212, a hybrid therapeutic for multiple CNS malignancies, as it builds visibility ahead of clinical readouts.